Product Characterization & Attribute Analysis - ProtaGene

Biologic Drug Analytics

Product Characterization & Attribute Analysis

hero-animation

Product Characterization & Attribute Analysis

With more than 20 years of working in complex biologic drug characterization, we have extensive experience developing and establishing protein characterization methods.

According to the ICH Q6B guideline, the analytical characterization includes primary, secondary and higher order structural assessment, the biological activity and the analysis of product and process impurities.

We help our clients generate the data needed for product characterization from candidate selection through regulatory submission and commercial product QC testing.

Complete IND/IMPD and BLA/MAA phase-appropriate characterization including:

  • bullet Created with Sketch.

    Primary sequence and PTM analysis

  • bullet Created with Sketch.

    Intact and subunit analysis

  • bullet Created with Sketch.

    Disulfide linkage mapping

  • bullet Created with Sketch.

    Glycosylation characterization

  • bullet Created with Sketch.

    Forced degradation and low-level Impurity ID programs

  • bullet Created with Sketch.

    Host cell protein analysis/ELISA correlation by LC-MS

  • bullet Created with Sketch.

    Hydrogen deuterium exchange (HDX-MS)

  • bullet Created with Sketch.

    PEGylation and ADC DAR mapping

  • bullet Created with Sketch.

    Amino acid analysis/extinction coefficient determination

  • bullet Created with Sketch.

    Protein binding by SPR/Biacore

  • bullet Created with Sketch.

    Higher-order structure (HOS) characterization by AUC, CD, FTIR

Analytical Solutions from Research to Market

Group Created with Sketch.
Research
Preclinical
Group 2 Created with Sketch.

Discovery – Pre-clinical

Biologic Candidate Evaluation, Optimization and Selection into IND

Group 3 Created with Sketch.
Phase I
Phase II
Phase III
Group 4 Created with Sketch.

Phase I – Phase III

Release, Clinical Data and Characterization Packages for Accelerating Phase I-III Programs through BLA

Group Created with Sketch.
Registration
Market
Group 2 Created with Sketch.

Registration – Market

Commercial-Stage Comparability Testing by Qualified Advanced Methods

Biologic Therapeutics Platform Expertise

Our deep experience advancing a diverse range of therapeutic platforms from research through market help the ProtaGene team design highly effective analytical programs that de-risk development and accelerate timelines to your next key milestones. Key biologic development areas include:

  • bullet Created with Sketch.

    Recombinant proteins—including complex, highly glycosylated proteins

  • bullet Created with Sketch.

    Multi-subunit complexes—protein, nucleotide, ligand

  • bullet Created with Sketch.

    mAbs

  • bullet Created with Sketch.

    ADCs and protein conjugates

  • bullet Created with Sketch.

    PEGylated proteins

  • bullet Created with Sketch.

    Bispecifics/multispecifics

  • bullet Created with Sketch.

    Fusion proteins

  • bullet Created with Sketch.

    Enzyme replacement therapies

  • bullet Created with Sketch.

    Biosimilars

  • bullet Created with Sketch.

    Vaccines, including subunit/recombinant

Our Analytical Systems_Left Created with Sketch.

Analytical Systems

Enabled by state-of-the-art technology, ProtaGene offers an extensive range of analytical capabilities to support your biotherapeutic or gene & cell therapy projects.

Our Analytical Systems_right Created with Sketch.

Subscribe to Our Email List

Consent

Talk to Our Experts

Discover how ProtaGene can support your development programs

Contact Us